加拿大两省癫痫儿童疫苗接种覆盖率研究
该回顾性队列研究纳入加拿大曼尼托巴省和安大略省2005-2013年出生的儿童,比较癫痫与非癫痫儿童的疫苗接种覆盖率及及时性。结果显示,2岁和7岁时癫痫儿童与非癫痫儿童疫苗覆盖率无显著差异,但6个月前诊断癫痫的婴儿在2岁时疫苗覆盖率略低。
要点
- 癫痫儿童整体疫苗接种覆盖率与非癫痫儿童相当。
- 6个月前诊断癫痫的婴儿2岁时疫苗覆盖率略低。
- 癫痫儿童因感染并发症风险高,应优化早期疫苗接种。
核心结论
- 癫痫儿童与非癫痫儿童相比未出现显著疫苗接种不足。
- 6个月前诊断癫痫的婴儿在2岁时疫苗覆盖率略低,但7岁时差异消失。
- 癫痫儿童疫苗接种及时性与非癫痫儿童相似。
研究设计与样本
- 回顾性队列研究,纳入2005-2013年出生儿童,分2岁和7岁队列。
- 2岁队列癫痫儿童16,558名(曼尼托巴653,安大略15,905)。
- 7岁队列癫痫儿童13,004名(曼尼托巴483,安大略12,521)。
主要发现
- 2岁时癫痫与非癫痫儿童疫苗覆盖率aOR为0.9(95%CI 0.8-1.1)。
- 7岁时aOR为1.0(95%CI 0.9-1.1)。
- 6个月前诊断癫痫的婴儿2岁时aOR为0.9(95%CI 0.8-0.9)。
- MMR第1剂和DTaP第4剂及时性在两组间相似。
关键数值与推荐
- MMR第1剂推荐于12月龄接种。
- DTaP第4剂推荐于18月龄接种。
- 疫苗覆盖率依据省级免疫规划评估。
临床怎么用
- 癫痫儿童应按常规推荐接种疫苗,尤其关注早期诊断的婴儿。
- 因癫痫儿童感染并发症风险高,应主动优化疫苗接种。
- 不可依赖群体免疫保护癫痫儿童,需确保个体接种。
局限性
- 回顾性研究设计可能受混杂因素影响。
- 仅纳入两个加拿大省份,外推性受限。
- 未报告具体疫苗覆盖率数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Children with epilepsy are at increased risk of complications from vaccine-preventable infections, yet information on vaccine coverage in these children is scarce. We aimed to compare vaccine coverage among children with epilepsy to children without epilepsy. STUDY DESIGN: We conducted a retrospective cohort study including all 2005-2013 births in Manitoba and Ontario, Canada, creating two cohorts: 2-year-olds and 7-year-olds (followed to age 2 and 7 years). We split each cohort into epilepsy and non-epilepsy subcohorts. We assessed vaccination coverage based on provincial schedules and determined timeliness of MMR (measles, mumps, rubella) dose 1 (recommended at 12 months) and DTaP (diphtheria, tetanus, pertussis) dose 4 (recommended at 18 months). We used logistic regression to calculate adjusted odds ratios (aORs) of the association between epilepsy and vaccination, combining both provincial estimates using random effects meta-analysis. RESULTS: We included 16,558 2-year-olds (Manitoba, 653; Ontario, 15,905) and 13,004 7-year-olds (Manitoba, 483; Ontario, 12,521) with epilepsy. At age 2 years, the aOR for up-to-date vaccination among children with versus without epilepsy was 0.9 (95% confidence interval 0.8-1.1); at age 7 years it was 1.0 (0.9-1.1). Infants diagnosed with epilepsy before age 6 months were less likely to be up-to-date at age 2 years (0.9; 0.8-0.9), although this difference disappeared by age 7 years. Vaccine timeliness was similar between children with and without epilepsy for MMR dose 1 and DTaP dose 4. CONCLUSIONS: Overall, this study suggests that children with epilepsy are not significantly under-vaccinated compared to their peers without epilepsy. As children with epilepsy are at a higher risk of complications from vaccine-preventable diseases, vaccination in children with epilepsy should be optimized, especially early in life, as these children may not be able to rely on herd protection.
引用
- Righolt CH, Pabla G, Donelle J, et al. Vaccine coverage among children with epilepsy in two Canadian provinces: A Canadian immunization research network study. Vaccine. 2021. PMID: 33722410. doi:10.1016/j.vaccine.2021.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。